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Tissue-Speciﬁc Metabolic Proﬁles After Prolonged Cardiac Arrest
Reveal Brain Metabolome Dysfunction Predominantly After
Resuscitation
Jaewoo Choi, PhD;* Muhammad Shoaib, BA;* Tai Yin, MD, PhD; Gautam Nayyar, BS; Koichiro Shinozaki, MD, PhD; Jan F. Stevens, PhD;
Lance B. Becker, MD; Junhwan Kim, PhD
Background-—Cardiac arrest (CA) has been a leading cause of death for many decades. Despite years of research, we still do not
understand how each organ responds to the reintroduction of blood ﬂow after prolonged CA. Following changes in metabolites of
individual organs after CA and resuscitation gives context to the efﬁciency and limitations of current resuscitation protocols.
Methods and Results-—Adult male Sprague–Dawley rats were arbitrarily assigned into 3 groups: control, 20 minutes of CA, or
20 minutes of CA followed by 30 minutes of cardiopulmonary bypass resuscitation. The rats were euthanized by decapitation to
harvest brain, heart, kidney, and liver tissues. The obtained tissue samples were analyzed by ultra-high-performance liquid
chromatography–high-accuracy mass spectrometry for comprehensive metabolomics evaluation. After resuscitation, the brain
showed decreased glycolysis metabolites and fatty acids and increased amino acids compared with control. Similarly, the heart
displayed alterations mostly in amino acids. The kidney showed decreased amino acid and fatty acid pools with severely increased
tricarboxylic acid cycle metabolites following resuscitation, while the liver showed minimal alterations with slight changes in the
lipid pool. Each tissue has a distinct pattern of metabolite changes after ischemia/reperfusion. Furthermore, resuscitation worsens
the metabolic dysregulation in the brain and kidney, while it normalizes metabolism in the heart.
Conclusions-—Developing metabolic proﬁles using a global metabolome analysis identiﬁes the variable nature of metabolites in
individual organs after CA and reperfusion, establishing a stark contrast between the normalized heart and liver and the
exacerbated brain and kidney, only after the reestablishment of blood circulation. ( J Am Heart Assoc. 2019;8:e012809. DOI: 10.
1161/JAHA.119.012809.)
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C ardiac arrest (CA) is a leading cause of death in theUnited States, with an overall survival rate of approxi-
mately 10%. While many patients are temporarily resuscitated,
poor neurological outcome is a major cause for the high
mortality rate.1–3 Because CA is a time-dependent pathology,
it is imperative to quickly initiate resuscitation protocols,
which can successfully treat many patients who experience
CA; however, the longer a patient resides in the ischemic
phase, the likelihood of his/her survival decreases drasti-
cally.4 As such, survival is signiﬁcantly lower with patients
who experience prolonged CA. Despite improved resuscitation
guidelines and new therapeutic interventions, restoring blood
ﬂow to ischemic organs remains the primary constituent of
current resuscitation medicine5–8; furthermore, it is com-
monly known that reperfusion may also produce elements of
“reperfusion injury.”9 Although reperfusion is imperative for
survival, we do not fully understand the metabolic alterations
that occur after restoring blood ﬂow to each organ, partic-
ularly after a prolonged duration of cardiac arrest.
Under ischemic conditions, numerous cellular pathways
are altered and these alterations in turn cause changes in the
content and/or the composition of metabolites in tissues;
metabolites are important indicators of physiological or
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pathological states of organs.10 Therefore, following meta-
bolic alterations caused by the full body ischemia of CA and
alterations that remain or newly arise after reperfusion of
these ischemic tissues will help assess the effects of the
restoration of blood ﬂow on individual organs.
Current metabolomics approach allows the simultaneous
measurement of numerous metabolites in various pathways,
explicating many fundamental questions about cellular phys-
iology/metabolism.11 Not only is this approach becoming
more essential in discovering new molecular biomarkers, but
it has been useful in understanding the overall cellular
metabolism in organs.12–14 This is of great advantage in
studying CA pathology, where whole-body ischemia and
subsequent resuscitation affect multiple pathways in multiple
organs simultaneously.15–22 These prior studies have mainly
used isolated organ ischemia/reperfusion injury models,
which do not accommodate for whole-body ischemia, which
is a distinctive feature of cardiac arrest, thus limiting the
applicability of their metabolic ﬁndings in understanding CA
pathology.
A lack of a severe injury model that mimics the human
condition of prolonged CA has also been an obstacle in CA
research. A majority of patients with CA die of prolonged CA
within several hours, even with advanced life support.
However, most preclinical studies are established on the
basis of CA models with relatively short CA times (up to
10 minutes), after which animals can survive for several days
without any treatment.23,24 Therefore, models with short CA
time represent only a minor portion of patients who
experience CA with mild injury, and alterations observed in
these models have limited clinical applicability. The lack of a
severe injury model is partly attributable to the limitation of
conventional chest compression to resuscitate animals up to
10 minutes after CA.
To overcome this limitation, we previously established a
customized rat model of prolonged CA followed by resusci-
tation using cardiopulmonary bypass (CPB). The rodent CPB
model mimics elements of human extracorporeal membrane
oxygenation resuscitation,25–27 which provides better survival
and neurological outcomes compared with conventional
cardiopulmonary resuscitation (CPR) in human patients with
CA.28–31 In animal experiments, CPB resuscitation can restore
native heart contractions and full reperfusion after 30 min-
utes of CA, allowing the examination of postresuscitation
metabolic status after sustained CA. Our model shows that
even if rats are able to achieve return of spontaneous
circulation (ROSC), their survival time is 4 hours after
resuscitation, which is translatable to most human patients,
who also die within a few hours despite achieving ROSC,
validating that our model mimics human disease.
Using this model, we applied a global metabolomics
strategy to evaluate how each tissue responds to 20 minutes
of prolonged CA and then 30 minutes of reperfusion, and
whether the metabolic alterations are seen during ischemia or
rather develop during reperfusion. An ultra-high-performance
liquid chromatography (LC)–high-accuracy mass spectrometry
(MS) system was used to follow the changes in lipids, amino
acids, carbohydrates, and other metabolites in the brain,
heart, kidney, and liver. This information about tissue-speciﬁc
metabolite alterations can be used to further understand the
pathophysiological changes that occur following ischemia/
reperfusion as a function of cardiac arrest, especially in the
brain. Furthermore, the nuances of metabolite abnormalities
in different tissues can be used to develop novel, more
targeted therapeutic strategies to treat the metabolic injury in
patients with CA.
Materials and Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Chemicals and Materials
Reagents used for metabolomics analyses include methanol,
acetonitrile, and ultra-pure water (LC-MS grade; EMD
Millipore, Gibbstown, NJ); formic acid, acetic acid, ammo-
nium hydroxide (Optima LC-MS Grade; Fisher Chemical,
Pittsburgh, PA); and ammonium carbonate (Sigma Aldrich,
St. Louis MO).
Clinical Perspective
What Is New?
• Metabolic dysregulations observed after cardiac arrest and
subsequent resuscitation demonstrate a unique, individual-
ized proﬁle for each organ.
• Metabolic alterations after 20 minutes of cardiac arrest are
found to be more severe in the heart and kidney than in the
brain and liver.
• Metabolic alterations after 30 minutes of cardiopulmonary
bypass resuscitation are rescued in the heart and liver but
become more severe in the brain and kidney.
What Are the Clinical Implications?
• More severe metabolic dysregulation of the brain indicates
that brain damage may directly be caused by resuscitation
rather than ischemia.
• This result shows a critical limitation of current resuscitation
protocols, requiring the development of more targeted
interventions for individual organs with a particular empha-
sis on the brain.
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Animals and Surgical Procedures
The experimental protocol was approved by the Institutional
Animal Care and Use Committee of the Feinstein Institute of
Medical Research. All procedures were conducted following
the approved protocol. Adult male Sprague–Dawley rats (3–
4 months of age, weight 410–450 g; Charles River Produc-
tion, Wilmington, MA) were used for this study. Rats were
maintained under a 12-hour light/dark cycle with free
access to food and water and used without starvation. Rats
were arbitrarily assigned into 3 groups: control, in which no
CA is performed, 20 minutes of CA, and 20 minutes of CA
followed by 30 minutes of resuscitation via CPB. This study
used an established asphyxia-induced CA rat model, of
which the detailed surgical procedures have been reported
previously.25,26 Brieﬂy, rats were anesthetized with 4%
isoﬂurane and ventilated with an intubated catheter with
2% isoﬂurane. After the injection of heparin (150 U) and
vecuronium (1 mg), asphyxia was induced by stopping the
ventilator and isoﬂurane discontinued. Animals in the CA
group were euthanized 20 minutes after the initiation of
asphyxia. In the resuscitation group, resuscitation was
started following 20 minutes of asphyxia with the initiation
of CPB ﬂow and resumption of ventilation. All rats used in
this study achieved ROSC. After 30 minutes of CPB
resuscitation, rats were euthanized by decapitation to
harvest brain, heart, kidney, and liver tissue samples or
maintained on the ventilator to measure survival time. Time
to reach CA is deﬁned as mean arterial pressure dropping
below 20 mm Hg.26,32 Time to achieve ROSC was monitored
to ensure consistency in our animal model. Control group
animals were euthanized by decapitation 7 minutes after
administration of isoﬂurane to ensure deep anesthesia
before harvesting tissues. We chose 20-minute CA for this
study because it produces a severe injury to the animal
model that mimics most human patients in critical condi-
tions, but also retains the potential to be treatable with
interventions. The harvested tissues from all 3 groups were
immediately ﬂash-frozen in liquid nitrogen, pulverized, and
stored at 80°C until analysis. Six animals were included in
each group, and each animal was used to generate one data
point except for liver in the CPB group, which has only 5
samples because of failure in MS analysis. Data are
represented as meanSEM.
Sample Extraction
The pulverized tissues (50 mg, n=6 group) were transferred to
1.5-mL Eppendorf tubes. Extraction solvents (500 lL, 50:50
v/v methanol:acetonitrile) were added into the tubes, and the
mixture was homogenized with 0.5-mm zirconium oxide beads
(Next Advance, Inc., Averill Park, NY, product #ZrOB05) using
a countertop bullet blender (Next Advance, Inc.) at 4°C for
4 minutes. Samples were incubated for 1 hour at 20°C,
then centrifuged at 4°C at 15 000g for 10 minutes. Aliquots
(400 lL) of the upper layer were transferred individually to
new tubes and evaporated in a stream of nitrogen gas. The
residue was reconstituted in solution (200 lL, 50:50 v/v
acetonitrile:water), vortexed for 20 seconds, centrifuged at
4°C at 15 000g for 5 minutes, and then stored at 80°C until
analysis via LC–tandem mass spectrometry (MS/MS). To
ensure the stability and repeatability of the LC–MS system,
quality control samples (n=4), which were generated by
pooling 10-lL aliquots from all tissues samples extracts, were
analyzed along with the samples.
LC-MS/MS for Metabolomics Analysis
Chromatography was performed with a Shimadzu Nexera
system (Shimadzu, Columbia, MD) coupled to a high-
resolution hybrid quadrupole time-of-ﬂight mass spectrometer
(TripleTOF 5600; SCIEX, Framingham, MA). For each sample,
2 different analysis methods were performed using reverse-
phase or hydrophilic interaction LC columns.33 In reverse-
phase LC, chromatographic separations were carried out
using a 2.19100 mm Titan C18 column (1.9 lm, Supelco,
Bellefonte, PA) for positive and negative ion analyses. The
sample injection volume was 5 lL, and the ﬂow rate was
0.2 mL/min. The mobile phases consisted of water (A) and
methanol (B), both with 0.1% formic acid. The gradient was as
follows: an initial hold at 3% B for 0.5 minutes, followed by a
gradient of 3% to 20% B in 5 minutes, to 55% B in 13 minutes,
to 95% B in 15.5 minutes, held until 18.5 minutes, then a
shift to 5% B at 19 minutes until 25 minutes. The column
temperature was held at 45°C. In metabolomics hydrophilic
interaction LC analysis, separation was carried out using a
2.19150 mm SeQuant ZIC-pHILIC (5 lm, EMD Millipore,
Billerica, MA).33 The ﬂow rate was 0.2 mL/min and the
injection volume was 5 lL. The 2 mobile phases consisted of
20 mmol/L ammonium carbonate, pH 9.2 with ammonium
hydroxide in water (A) and acetonitrile (B). The gradient was
as follows: an initial hold at 80% B for 2 minutes, followed by
a gradient of 80% to 20% B in 17 minutes, then a shift to 80%
B at 17.1 minutes until 22 minutes. The column temperature
was 45°C.
Time-of-ﬂight–MS was operated with an acquisition time of
0.25 seconds and a scan range of 70 to 1000 Da. MS/MS
acquisition was performed with collision energy set at 35 V and
collision energy spread of 15 V. Each MS/MS scan had an
accumulation time of 0.12 seconds and a range of 40 to
1000 Da using information-dependent acquisition (IDA). The
source temperature was set at 500°C in reverse phase, 550°C in
hydrophilic interaction LC and IonSpray voltage at 5.5 kV in
positive ion mode and4.5 kV negative ion mode, respectively.
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Data Processing
Targeted metabolomics data were processed using Peak View
2.1 and MultiQuant software version 3.0.2 (SCIEX). Chro-
matographic peaks of targeted metabolites were annotated
using the extract ion chromatogram lists on the basis of high-
accuracy MS, MS/MS fragmentation, isotopic distribution,
and retention time compared with an in-house library of 635
metabolite standards (IROA Technologies, Bolton, MA). In
addition to the IROA database, the fragmentation spectra of
all peaks were searched through Metlin and HMDB. Each
identiﬁed metabolite was quantiﬁed by integrating peak area
using MultiQuant software. The quantitative analysis was
based on the total peak areas of extracted ion chro-
matograms of feature ions.
Multivariate and Statistical Analyses
Principal component analysis was used to examine the
metabolic proﬁle to reﬂect the overall changes following CA
and following resuscitation compared with control in the
brain, heart, kidney, and liver tissues. The principal compo-
nent analysis plot was generated with MetaboAnalyst (v4.0)
using normalized data (Pareto scaling feature, log transfor-
mation). Second, changes in individual metabolites were
assessed and diagrammed in well-recognized biochemical
pathways. However, pathways may be carried out differently
among the 4 tissues. Statistical analyses for each metabolite
were performed with 1-way ANOVA with Bonferroni’s multiple
comparison tests using GraphPad Prism 6.0 software
(GraphPad, La Jolla, CA). Finally, Pathway Analysis using
Metaboanalyst (v4.0) was used to evaluate the impact of
individual metabolite alteration on different metabolic path-
ways. The levels of each metabolite were converted to relative
changes compared with control values, which were set as 1,
allowing 1 control column for all 4 tissues. To control for false
discovery rates for these metabolomics data during follow-up
analyses, statistical signiﬁcance was determined by q values
(false discovery rate corrected P values) using an adaptive
linear step-up procedure; q<0.05 was considered to be
signiﬁcant.
Results
Physiological Outcome
The average time to reach CA was 18642 seconds. After
the initiation of CPB resuscitation, the average time to display
heart electrical activity was 4527 seconds and the time to
achieve ROSC was 20081 seconds. The average survival
time of rats after 20 minutes of CA and 30 minutes of CPB
resuscitation was 3 to 80.38 hours with limited brain
function, seen as a lack of response to toe pinch and corneal
agitation. This limited brain function and poor survival
outcome is analogous to human patients with CA with severe
injury.
Principal Component Analyses
Principal component analysis was performed to screen
changes in the overall metabolic proﬁle in each organ after
20 minutes of CA and 30 minutes of CPB resuscitation
compared with control. The scores plot shown in Figure 1A
contains PC1 and PC2 values of 30.4% and 17.7% of data
variation, respectively, which represents a difference between
CA and CPB in each tissue. In the brain, there is no direct
cluster separation after 20 minutes of CA, but there is
signiﬁcant separation following 30 minutes of CPB resuscita-
tion. In the heart, signiﬁcant cluster separation from control
exists after CA, but no further separation follows resuscita-
tion. In the kidney, there is signiﬁcant separation following CA
and following resuscitation. The liver shows a signiﬁcant
separation following CA, which minimizes after resuscitation.
The loading plot (Figure 1B) shows the correlation of each
metabolite in each tissue between 20 minutes of CA and
30 minutes of CPB resuscitation. The data show that
acylcarnitines (ACs), for example, AC 6:0, AC 10:0, AC 14:1,
AC 14:2, and AC 16:1, with negative loading 1 (about 0.2)
and loading 2 (between ≥0.1 and 0.1) overlap in the brain and
liver after resuscitation, as shown in the score plot. This
correlation shows that changes in ACs are one of the main
reasons for the distinct metabolic proﬁles of the liver and
brain after CPB resuscitation. Similarly, citrate, a-ketogluta-
rate (oxoglutarate), malate, fumarate, and succinate in the
tricarboxylic acid (TCA) cycle are signiﬁcantly changed in
kidney tissue after CPB compared with control or CA. A
greater degree of change in free fatty acid content is seen in
the heart as compared with other organs after CA or CPB. In
summary, 20 minutes of CA results in a distinct metabolic
proﬁle for individual organs. During 30 minutes of CPB
resuscitation, the heart and liver have the most potential to
be normalized; the brain and kidney show progressive
abnormalities during this same reperfusion period.
We also provide a heatmap of targeted metabolites within
pathways as a visual representation of the relative changes in
each metabolite among control, 20-minute CA, and 30-minute
CPB resuscitation groups for all 4 tissue types (Figure 2). The
clustering tree was built on the basis of the distance metrics
of Pearson correlation coefﬁcient. All data are plotted in
clusters showing relative values when compared with a
control group, which is a superimposition of the control values
for all 4 organs. For example, oxoglutarate is decreased in the
brain and liver but increased in the heart and kidney after CPB
resuscitation when compared with control.
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Changes in Individual Metabolites Following CA
and CPB Resuscitation
Statistically signiﬁcant changes in individual metabolites in
each tissue after 20 minutes of CA followed by 30 minutes of
CPB resuscitation are shown in Figures 3 and 4. These
metabolic pathway maps provide TCA cycle intermediates,
energy-generating metabolites of glycolysis, amino acids, fatty
acids, and urea cycle metabolites. This diagrammatic pathway
map was constructed to facilitate visualization of post-CA and
post-CPB resuscitation changes in metabolic constituents
based on well-accepted metabolic pathways.33 The color code
represents a statistically signiﬁcant increase (red) or decrease
(green) with P<0.05 in metabolites after resuscitation com-
pared with control, emphasizing the metabolic status in
resuscitated rats.
In the brain tissue, 20 minutes of CA and subsequent 30-
minute CPB resuscitation results in signiﬁcant changes in the
amino acid pool; most of these changes occur mainly after
resuscitation (Figure 3A). Particular attention is drawn to
histidine, leucine, isoleucine, valine, serine, and methionine,
which all increased above control levels after 20 minutes of
CA. Moreover, these amino acids, along with glutamine,
glycine, and lysine all signiﬁcantly increased above control
after 30 minutes of CPB resuscitation. The only amino acids
that decreased after resuscitation compared with control were
aspartate and glutamate, while the remaining measured amino
acids remained unchanged throughout ischemia and
reperfusion. Unlike the amino acid pool, the fatty acid pool in
the brain remained relatively normal; after 20 minutes of CA,
linoleic acid was signiﬁcantly decreased. After 30 minutes of
CPB resuscitation, linoleic and linolenic acids were signiﬁcantly
decreased. The brain tissue shows a decrease in glycolytic and
TCA cycle metabolites, such as fructose-1,6-bisphosphate, 3-
phosphoglycerate, and citrate after 20 minutes of CA; how-
ever, after 30 minutes of CPB resuscitation, 3-phosphoglyce-
rate signiﬁcantly decreased. Urea cycle metabolites, such as
arginine and proline, displayed a signiﬁcant elevation after
20 minutes of CA; however, 30 minutes of CPB resuscitation
resulted in variations in all major urea cycle metabolites, such
that arginine, citrulline, ornithine, and proline were all signif-
icantly increased, while glutamate was signiﬁcantly decreased.
In the heart tissue, the amino acid pool remained relatively
normal; 20 minutes of CA resulted in signiﬁcant elevation in
only threonine, valine, and isoleucine above control (Fig-
ure 3B). Resuscitation via 30 minutes of CPB resulted in
threonine and histidine elevation, while isoleucine returned to
control levels. The only amino acid that was signiﬁcantly
decreased after resuscitation was tryptophan. Heart tissue also
displayed an increase in stearic acid as the only fatty acid that
was altered after CA, which remained elevated after 30 min-
utes of CPB resuscitation. The heart tissue shows variations in
glycolytic and TCA cycle metabolites, such as a decrease in 3-
phosphoglycerate and an increase in oxoglutarate, succinate,
fumarate, and malate. However, 30 minutes of CPB resuscita-
tion resulted in the normalization of 3-phosphoglycerate and
Figure 1. A, Principal components analysis of metabolites from tissues after cardiac arrest and
resuscitation. B, Loading plot of metabolites. All 4 organs have distinct metabolic proﬁles after cardiac
arrest and after resuscitation, with the brain being the one organ that exhibited drastic alterations only after
resuscitation. We superimposed the controls of all 4 organs into 1 point. As such, the “control” serves as a
control for all 4 organs. B indicates brain; CA, cardiac arrest; CON, control; CPB, cardiopulmonary bypass; H,
heart; K, kidney; L, liver.
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succinate, but lack of normalization of fumarate and malate.
Urea cycle metabolites, such as proline signiﬁcantly increased
only after resuscitation. During CA, most of the urea cycle
metabolites were not altered signiﬁcantly.
The pool of measured amino acids in the kidney tissue
displayed an intriguing pattern of dysregulation compared with
the other tissues; the only amino acids that were unaffected by
CA were glutamine, threonine, alanine, and valine, while the
remaining measured amino acids were signiﬁcantly decreased
(Figure 4A). Furthermore, 30 minutes of CPB resuscitation
resulted in even more dysregulation; all measured amino acids
with the exception of glutamate, alanine, and valine were
signiﬁcantly decreased. Kidney tissue also displayed a signif-
icant increase in palmitic and stearic acids after 20 minutes of
CA. However, 30 minutes of CPB resuscitation resulted in a
signiﬁcant decrease in linoleic and linolenic acids, while stearic
acid returned to control levels. The general trend of lipids in the
kidney is that they increase after ischemia, but either return to
or fall below control levels after resuscitation. The kidney
shows variations in glycolytic and TCA cycle metabolites, such
as a signiﬁcant elevation in 3-phosphoglycerate and oxoglu-
tarate after 20 minutes of CA. However, CPB resuscitation
resulted in a signiﬁcant increase in citrate, oxoglutarate,
succinate, fumarate, malate, and oxaloacetate. The urea cycle
metabolites were mostly altered after 30 minutes of CPB
resuscitation in the kidney. Arginine and proline were signif-
icantly decreased after CA, but after CPB, arginine, citrulline,
ornithine, and proline were all decreased.
The liver displayed the most resistance to amino acid
alterations, such that 20 minutes of CA elevated asparagine
Figure 2. Heatmap. The heatmap provides intuitive visualization of a data table. Each colored cell on the
map corresponds to peak area average value in the data table, with samples in columns and features/
compounds in rows. Colors indicate Z score (standard deviation from the mean) with red representing
increased and blue representing decreased with respect to control. The heatmap was generated with
MetaboAnalyst 4.0 using normalized data (log transformation, Pareto scaling) using Euclidean distance
measure. B indicates brain; CA, cardiac arrest; CON, control; CPB, cardiopulmonary bypass; H, heart; K,
kidney; L, liver.
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Figure 3. Assembly of the major metabolic pathways in the brain (A) and heart (B). Postresuscitation metabolites are
shown, with the corresponding changes from control to cardiac arrest to resuscitation shown in graphs adjacent to
respective metabolites. The colors correspond to the level of metabolites after resuscitation: red is increased levels, while
green is decreased levels. TCA indicates tricarboxylic acid.
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Figure 4. Assembly of the major metabolic pathways in the kidney (A) and liver (B). Postresuscitation metabolites are
shown, with the corresponding changes from control to cardiac arrest to resuscitation shown in graphs adjacent to
respective metabolites. The colors correspond to the level of metabolites after resuscitation: red is increased levels, while
green is decrease levels. TCA indicates tricarboxylic acid.
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levels signiﬁcantly, which returned to control levels after
resuscitation. CA resulted in a signiﬁcant decrease in myristic,
palmitic, palmitoleic, oleic, linoleic, and linolenic acids, which
all normalized after 30 minutes of CPB resuscitation (Fig-
ure 4B). The liver tissue shows variations in glycolytic and
TCA cycle metabolites, such as a signiﬁcant decrease in
fructose-1,6-bisphosphate and a signiﬁcant increase in coen-
zyme A after CA. However, after resuscitation, fructose-1,6-
bisphosphate was normalized. There was relative resistance
to changes in the urea cycle metabolites in the liver, such that
arginine and citrulline were both signiﬁcantly elevated follow-
ing CA, while after CPB, liver tissue normalized most of the
metabolites.
Changes in Individual AC Species Following CA
and CPB Resuscitation
AC species are fatty-acyl chains connected to carnitine
molecules via an ester bond to be oxidized via fatty acid
oxidation.34 Figure 5 shows the comparison of many AC
species between control, 20-minute CA, and 30-minute CPB
resuscitation in all 4 tissues. In brain tissue, CA resulted in
elevations in AC 2:0 and AC 6:0 but a decrease in AC 16:2
and AC 18:2 when compared with control. Resuscitation-
induced alterations of AC species when compared with post-
CA are as follows: decreased levels were observed in only AC
2:0, while increased levels were observed in AC 6:0, AC 10:0,
AC 14:2, AC 14:0, AC 16:2, AC 16:0, AC 18:2, AC 18:1, and
AC 20:4. Resuscitation resulted in an increase in AC 6:0, AC
10:0, and AC 16:0 as compared with control.
In heart tissue, 20 minutes of CA resulted in elevations in
AC 6:0, AC 8:0, and AC 10:0, while decreased levels were
observed in AC 14:2, AC 16:2, AC 16:1, AC 16:0, AC 18:2,
and AC 18:1 when compared with control. After 30 minutes of
CPB resuscitation, increased levels of AC 16:0, AC 18:2, and
AC 18:1 and decreased levels of AC 6:0, AC 8:0, and AC 14:1
were found when compared with post-CA. After resuscitation,
AC species that were decreased were AC 14:2, AC 14:1, and
AC 16:2, while AC 10:0 was increased when compared with
control. During ischemia, longer-chain fatty acids decreased
Figure 5. Acylcarnitine species with their relative alterations when compared between control, 20 minutes of cardiac arrest, and resuscitation
shown for individual tissues. As compared with control, the brain shows a general decreasing trend of acylcarnitine species after cardiac arrest,
which mostly increase following resuscitation without a distinct pattern (A); the heart shows an increase in short-chain and a decrease in long-
chain acylcarninties after cardiac arrest, which mostly normalize following resuscitation (B); the kidney shows a generalized decrease in the
levels of acylcarnitines after resuscitation (C); the liver has minimal changes after cardiac arrest and has a general increase in acylcarnitine
levels following resuscitation (D). *P<0.05 between cardiac arrest or resuscitation and control; ‡P<0.05 between resuscitation and cardiac
arrest. AC indicates acylcarnitine; CA, cardiac arrest; CON, control; CPB, cardiopulmonary bypass.
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compared with control, while shorter-chain fatty acids
increased; however, resuscitation results in more normaliza-
tion across the board.
In kidney tissue, CA resulted in elevation in only AC 16:0
when compared with control. Resuscitation resulted in a
decrease from CA in AC 2:0, AC 8:0, AC 10:0, AC 14:2, AC
16:1, AC 16:0, AC 18:2, and AC 18:1. When compared with
control, AC species that were decreased after resuscitation
were AC 6:0, AC 8:0, AC 10:0, AC 14:2, AC 14:1, AC 16:2, AC
16:1, AC 18:2, and AC 18:1. The kidney was unable to
normalize ACs after resuscitation, resulting in a gener-
ally diminished lipid reserve after 30 minutes of CPB
resuscitation.
In liver tissue, CA resulted in elevation of one major AC
species, AC 6:0. However, resuscitation resulted in an
increase in AC 14:2, AC 14:1, and AC 16:2 when compared
with control, and AC 14:2, AC 14:1, AC 16:2, and AC 18:2
when compared with post-CA. The general trend observed
following resuscitation in the liver is that there is an increased
level of AC species.
Analysis of Speciﬁc Metabolite Pathway
Deviations
To further assess the impact of the observed metabolic
alterations, we performed a pathway analysis based on the
Kyoto Encyclopedia of Genes and Genomes database using
MetaboAnalyst (v4.0). This analysis uses a database of
predeﬁned metabolites in various individual or overlapping
pathways to identify the most signiﬁcantly affected pathways.
Figure 6 highlights the altered pathways following CA and
following resuscitation in the brain, heart, kidney, and liver.
The detailed list of pathways that were changed following
20 minutes of CA and 30 minutes of CPB resuscitation are
provided in Tables S1 through S8.
In the brain, no pathways were found to be signiﬁcantly
changed upon 20 minutes of CA compared with control
(q>0.05) (Figure 6A). However, 30 minutes of CPB resuscita-
tion compared with post-CA in brain tissue showed signiﬁcant
changes in 33 pathways (Figure 6B). Of these signiﬁcantly
altered pathways, the most notable metabolites were involved
in aminoacyl-tRNA biosynthesis; arginine and proline meta-
bolism; and alanine, aspartate and glutamate metabolism,
among others in CA compared with CPB in brain tissue.
In heart tissue, alanine, aspartate, and glutamate metabo-
lism; linoleic acid metabolism; arginine and proline metabo-
lism; and glycine, serine, and threonine metabolism showed
signiﬁcant alterations after 20 minutes of CA followed by
30 minutes of CPB resuscitation compared with control; 9
metabolic pathways were signiﬁcantly altered after CA when
compared with control (Figure 6C). Aminoacyl-tRNA biosyn-
thesis metabolism among the 13 pathways after CPB when
compared with control showed the lowest q value (0.02), but
the alanine, aspartate, and glutamate metabolism pathway
showed the high-impact value (0.75) (Figure 6D).
In kidney tissue, 24 pathways were signiﬁcantly changed
after CA compared with control, and lysine biosynthesis and
purine metabolism were shown with the lowest q value (0.01)
(Figure 6E). Following resuscitation, 46 pathways remained
signiﬁcantly altered compared with control, with nicotinate
and nicotinamide metabolism, and phenylalanine metabolism
having the lowest q values (Figure 6F). In liver tissue, although
a-linolenic acid metabolism, linoleic acid metabolism, and
fatty acid metabolism showed the lowest q values, none of
metabolic pathways were signiﬁcantly altered after CA or after
CPB resuscitation (Figure 6G and 6H).
Discussion
CA is a time-sensitive pathology in which many patients
succumb to the damage, especially in the brain, that ensues
because of prolonged ischemia and the subsequent metabolic
alterations.25–27,35,36 We applied a global metabolomics anal-
ysis on 4 major organs, the brain, heart, kidney, and liver, after
20 minutes of CA, or 20 minutes of CA followed by 30 minutes
of CPB resuscitation in our rat model of asphyxia-induced
cardiac arrest. This severe injury model mimics the metabolic
status and pathological injury of a majority of human CA
patients.25,36,37 Our analysis demonstrates 3 novel ﬁndings: (1)
the brain metabolome is more sensitive to alterations during
resuscitation than during ischemia, illustrating the necessity of
resuscitation protocols to focus on the brain; (2) each organ has
a unique metabolic proﬁle, which provides insight on organ-
speciﬁc targets for future resuscitation therapies; and (3) the
strengths of a global metabolomics analysis supersedes that of
isolated organs, which has been used by prior studies.
Therefore, by improving current resuscitation methods with
an emphasis on alleviating individual organ metabolome
alterations, particularly in the brain, we can not only increase
the survival of patients suffering frommajor brain damage after
CA but also improve the survival of patients who are unable to
immediately achieve ROSC.
People affected by longer durations of CA are greater in
prevalence and have a worse survival rate than those suffering
from a shorter duration. For this study, we have chosen
20 minutes of CA, which results in the death of rats within
18 hours, exemplifying the severity of this injury. This
represents a majority of CA patients, who die within a day
after achieving ROSC. Additionally, omega-3 fatty acid
treatment improved rat survival after 20 minutes of CA38
indicating that this degree of injury, although severe, still
retains the potential of being a treatable injury. Traditionally,
the longer durations of CA are not amenable to resuscitation
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Figure 6. Pathway analysis. Analyses are based on all annotated metabolites (n=6; log transfor-
mation, Pareto Scaling) and pathway enrichment of signiﬁcant metabolites in control vs cardiac arrest
and control vs resuscitation using metabolic data sets, which were generated with MetaboAnalyst
(4.0). Any data points above the red dotted line are statistically signiﬁcant (–Log false discovery
rate=1.3 is equal to q=0.05). The brain shows no signiﬁcant changes in any pathway after cardiac
arrest (A). However, resuscitation results in signiﬁcant pathway alterations (B). Cardiac arrest alters
some pathways in the heart (C), while resuscitation results in a decrease in the severity of pathway
alterations (D). The kidney has many pathways that are affected by cardiac arrest (E), and similar to
brain, the kidney, after resuscitation, demonstrates a greater number of pathways that are signiﬁcantly
altered (F). The liver does not demonstrate any pathway signiﬁcantly altered after cardiac arrest or
resuscitation (G and H). CA indicates cardiac arrest; CON, control; CPB, cardiopulmonary bypass.
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or treatment. However, we have created this model of
20 minutes of CA that closely mimics a majority of human
patients. This model is valuable for examining the key
metabolic pathways that may be related to improving survival
as key therapeutic targets.
The brain’s metabolic pattern suggests an increased
susceptibility during reperfusion, which is compounded to
any damage inﬂicted during ischemia as seen in Figures 1
and 3A. The pathway analysis conﬁrms minimal changes in
the brain metabolome after ischemia and severe changes
after resuscitation. This is consistent with our previous
report that reperfusion results in only brain mitochondria
experiencing cardiolipin alterations supplementing the injury
already attained from ischemia.39 The other organs also
demonstrated distinct metabolic proﬁles. The heart and liver
normalized the ischemia-induced alterations of their meta-
bolome after reperfusion, which bolsters our previous data
that these organs recover normal mitochondrial activity after
reperfusion.40 One important caveat is that the liver displays
marginally increased levels of AC species after reperfusion,
which is expected because a key function of the liver is to
regulate lipid metabolism (Figure 5).41 The liver may be
accruing fatty acids after reperfusion for its own metabolic
needs, and/or the liver is unable to effectively process and
transport fatty acids to other tissues, resulting in an
increased accumulation. The kidney displays severe metabo-
lite alterations following 20 minutes of CA, which further
worsen following 30 minutes of CPB resuscitation; this
serves as evidence that poor recovery of its metabolites to
homeostatic levels is consistent with our prior studies
showing that the kidney has lower-than-normal mitochondrial
function following resuscitation.40 The kidney was the only
tissue observed to have a signiﬁcant elevation in TCA
metabolites, signifying diminished TCA cycle efﬁciency and/
or turnover. Overall, our data suggest that reperfusion
results in more normalized metabolites in the heart and liver
but more dysregulated metabolic proﬁles in the brain and
kidney.
Our global metabolomics analysis demonstrates that the
brain, heart, kidney, and liver all have broad metabolic
alterations responding to ischemia and reperfusion with a
distinctive pattern, such that one organ displays a dramatic
ﬂuctuation in speciﬁc metabolite pools that may not be seen
in other organs. This approach is valuable because several
metabolites can be simultaneously screened and assessed
for signiﬁcant changes in each organ directly caused by this
pathology.42 Many prior studies on the metabolic dysregula-
tion attributable to ischemia/reperfusion have focused on
individual tissues, such as inducing ischemia via direct
ligation of the blood supply to the kidneys,18,20,43–45
brain,15,17,19,46 heart,16,47 or liver15,48–50 without focusing
on the metabolic interplay between organs during ischemia/
reperfusion. Direct ligation experiments that induce ischemia
to a particular organ are valuable in determining the effects
of ischemia/reperfusion. In fact, it has been shown that
injury to one organ can cause some alterations in other
organs.51 An example of this phenomenon is that a few
studies found succinate accumulation in either the plasma,
brain, or heart tissues as a consequence of ischemia,19,52,53
while another study found that succinate increased univer-
sally when the brain, heart, kidney, or liver were individually
subjected to ischemia via direct ligation.15 However, our
study and one other study showed no such universality.21
Although direct ligation models may also obtain similar
metabolite proﬁles for their individual diseased organs similar
to our model, these models tend to have the other organs
working in a near-physiological manner that can serve in a
compensatory role to help alleviate any pathological changes
that are happening to that one targeted organ. In our global
hypoperfusion model, all organs are being affected simulta-
neously in a closed system, an important facet of CA
pathology, which suppresses the aforementioned compen-
satory role. This makes our study unique because it mimics
the pathophysiological state of human cardiac arrest.54There-
fore, our data obtained from a simultaneous assessment of
metabolite alterations in various tissues in whole-body
ischemia provide vital information to assess the efﬁciency
of current resuscitation methods on the basis of simply
resuming blood circulation.
A limitation in this study is that we do not address any
causative or correlative interactions between different
metabolites, nor the role of each metabolite for CA pathology.
Additionally, an altered metabolic pathway may have a
signiﬁcant functional impact in one organ but not in other
organs. In fact, there may be regional speciﬁcity in individual
organs for a particular pathway, as organs are not homoge-
nous; for our analysis, we used whole organ samples. In this
light, the extent of metabolic alterations may not directly
correlate with the overall functional damage of each organ.
Therefore, the important question about why the alterations in
the brain and kidney become worse but normalize in the heart
and liver cannot be answered simply by pattern analysis. The
complex metabolic alterations may be caused by dysfunction
of the mitochondria, which serve as the major site of energy
generation. Energy generation is needed for normal physio-
logical functions and is required for repair.55 Energy-produ-
cing pathways are heavily affected following ischemia/
reperfusion.56,57 Furthermore, we have previously shown that
decreased mitochondrial function correlated with poor organ
function outcomes, particularly in the brain,40 which is also
consistent with the metabolic alterations seen in Figures 3
and 4, which we organized on the basis of mitochondrial
metabolism. As such, targeting the mitochondria may be a
good ﬁrst step in helping to identify and rescue the organ
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metabolic dysfunction after ischemia/reperfusion. Further
studies that manipulate certain pathways using interventions
such as hypothermia are required to understand the interac-
tions between metabolites, the signiﬁcance of alterations in
each metabolite in individual organs, and how these alter-
ations further affect other organs.
Despite these limitations, we found that resuscitation-
driven, not ischemia-induced, alterations are the main cause
for the overall brain metabolic alterations in these resusci-
tated rats. The worsening of brain metabolome after
resuscitation implicates reperfusion as the major cause for
brain damage and poor neurological function in these
animals. This phenomenon may be extrapolated to human
patients who clinically do not have neurological function
when exposed to long CA times even after resuscitation,
providing the impetus for modifying current resuscitation
methodologies to alleviate reperfusion brain injury.57,58 For
this purpose, metabolic alterations observed in our study
may provide potential target pathways for novel organ-
speciﬁc pharmacological therapies.59 Additionally, metabolic
alterations found in the kidney may also be important for
brain function. Kidney injury can result in changes in the
blood-brain barrier and neurotransmitter concentrations,
possibly potentiating neural damage.60 Once brain injury is
mitigated, the recovery of kidney function may be the driving
factor in long-term survival. This illustrates that the hypop-
erfusion from CA not only elicits damage in individual organs
but also directly impacts the relationship between the
organs, increasing the complexity of developing therapeutic
strategies to treat CA.
In conclusion, determining global metabolic alterations in
individual organs is valuable for understanding the metabolic
status of patients with CA after resuscitation. Moreover,
following the metabolic alterations that arise during CA and
how these alterations further change responding to resus-
citation is necessary to reevaluate the effects of current
resuscitation protocols, which mainly depends on the
restoration of blood circulation. A novel ﬁnding in our
comprehensive metabolic analysis is that the brain, heart,
kidney, and liver all undergo metabolic alterations following
20 minutes of CA, with the brain and liver less severe than
the heart and kidney. However, 30 minutes of CPB resus-
citation rescued metabolic alterations in the heart and liver
but caused additional metabolic alterations in the brain and
kidney. The more severe metabolome of the brain provides
the basis for poor neurological outcome after prolonged CA.
Overall, our results clearly show a critical limitation of
current resuscitation protocols. We clearly show the require-
ment for additional interventions in future studies that are
targeted to the individual organs to mitigate reperfusion
injury and ultimately improve neurological function and
overall survival.
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 Table S1. Pathway Analysis of brain tissue comparing control with cardiac arrest. 
Pathways Total 
Compounds 
Hits Raw p neg log 
p-value
Holm adjust. FDR neg log 
FDR 
Impact 
Aminoacyl-tRNA biosynthesis 75 18 0.0015988 6.4385 0.086336 0.056429 1.25 0.22536 
D-Arginine and D-ornithine metabolism 8 2 0.0031192 5.7702 0.16532 0.056429 1.25 0 
Valine, leucine and isoleucine biosynthesis 27 4 0.0057138 5.1649 0.29712 0.056429 1.25 0.0265 
Arginine and proline metabolism 77 8 0.0068467 4.984 0.34918 0.056429 1.25 0.41398 
Glyoxylate and dicarboxylate metabolism 50 4 0.0072827 4.9223 0.36413 0.056429 1.25 0.02984 
Valine, leucine and isoleucine degradation 40 3 0.0081805 4.806 0.40084 0.056429 1.25 0.0713 
Citrate cycle (TCA cycle) 20 5 0.0086167 4.7541 0.4136 0.056429 1.25 0.17318 
Cysteine and methionine metabolism 56 4 0.0087825 4.735 0.4136 0.056429 1.25 0.05003 
Pantothenate and CoA biosynthesis 27 3 0.0094048 4.6665 0.43262 0.056429 1.25 0.00854 
Sphingolipid metabolism 25 1 0.015619 4.1593 0.70287 0.076676 1.12 0 
Sulfur metabolism 18 1 0.015619 4.1593 0.70287 0.076676 1.12 0 
Biotin metabolism 11 1 0.051784 2.9607 1 0.21675 0.66 0 
Histidine metabolism 44 3 0.060211 2.8099 1 0.21675 0.66 0.14039 
Glycine, serine and threonine metabolism 48 5 0.060977 2.7973 1 0.21675 0.66 0.42039 
Propanoate metabolism 35 3 0.063113 2.7628 1 0.21675 0.66 0.05474 
Cyanoamino acid metabolism 16 4 0.064222 2.7454 1 0.21675 0.66 0 
Linoleic acid metabolism 15 1 0.072347 2.6263 1 0.22981 0.64 0.65625 
Purine metabolism 92 7 0.093434 2.3705 1 0.2803 0.55 0.14975 
Methane metabolism 34 3 0.11281 2.1821 1 0.31754 0.50 0.05444 
beta-Alanine metabolism 28 3 0.11761 2.1404 1 0.31754 0.50 0.01119 
Lysine degradation 47 3 0.13461 2.0054 1 0.3347 0.48 0.14675 
Nitrogen metabolism 39 10 0.13636 1.9925 1 0.3347 0.48 0.0083 
alpha-Linolenic acid metabolism 29 1 0.14809 1.91 1 0.33809 0.47 0.20335 
Tyrosine metabolism 76 3 0.15429 1.8689 1 0.33809 0.47 0.04724 
Phenylalanine metabolism 45 4 0.15652 1.8545 1 0.33809 0.47 0.11906 
Riboflavin metabolism 21 2 0.17263 1.7566 1 0.35855 0.45 0 
Lysine biosynthesis 32 4 0.18201 1.7037 1 0.36401 0.44 0.15084 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.18932 1.6643 1 0.36513 0.44 0 
Folate biosynthesis 42 1 0.20929 1.564 1 0.37367 0.43 0 
Fatty acid metabolism 50 3 0.21664 1.5295 1 0.37367 0.43 0.2426 
Butanoate metabolism 40 4 0.24922 1.3894 1 0.37367 0.43 0.10672 
Synthesis and degradation of ketone bodies 6 1 0.25935 1.3496 1 0.37367 0.43 0 
Inositol phosphate metabolism 39 1 0.25935 1.3496 1 0.37367 0.43 0 
Terpenoid backbone biosynthesis 33 1 0.25935 1.3496 1 0.37367 0.43 0 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.27407 1.2944 1 0.37367 0.43 0.008 
Porphyrin and chlorophyll metabolism 104 3 0.2757 1.2884 1 0.37367 0.43 0 
Taurine and hypotaurine metabolism 20 2 0.27959 1.2744 1 0.37367 0.43 0.03237 
Pyruvate metabolism 32 2 0.28167 1.267 1 0.37367 0.43 0.24876 
Glycolysis or Gluconeogenesis 31 2 0.28188 1.2663 1 0.37367 0.43 0.04202 
Tryptophan metabolism 79 2 0.28209 1.2655 1 0.37367 0.43 0.10853 
Thiamine metabolism 24 2 0.28371 1.2598 1 0.37367 0.43 0 
Fatty acid elongation in mitochondria 27 2 0.36359 1.0117 1 0.46747 0.33 0.26765 
Alanine, aspartate and glutamate metabolism 24 7 0.42249 0.86159 1 0.53057 0.28 0.75404 
Fatty acid biosynthesis 49 6 0.4651 0.76551 1 0.57005 0.24 0.0218 
Glutathione metabolism 38 5 0.47504 0.74436 1 0.57005 0.24 0.02214 
Selenoamino acid metabolism 22 1 0.51559 0.66244 1 0.57347 0.24 0 
Starch and sucrose metabolism 50 1 0.53711 0.62155 1 0.57347 0.24 0.01703 
Galactose metabolism 41 1 0.53711 0.62155 1 0.57347 0.24 0.00276 
Pentose phosphate pathway 32 1 0.53711 0.62155 1 0.57347 0.24 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.53711 0.62155 1 0.57347 0.24 0 
Primary bile acid biosynthesis 47 1 0.54161 0.6132 1 0.57347 0.24 0.00822 
Nicotinate and nicotinamide metabolism 44 4 0.76801 0.26395 1 0.79755 0.10 0.0015 
Pyrimidine metabolism 60 1 0.92166 0.081574 1 0.93905 0.03 0 
D-Glutamine and D-glutamate metabolism 11 2 0.97721 0.023056 1 0.97721 0.01 0.13904 
 Table S2. Pathway Analysis of brain tissue comparing control with CPB-resuscitation. 
Pathways Total 
Compounds 
Hits Raw p neg log 
p-value
Holm adjust. FDR neg log 
FDR 
Impact 
Alanine, aspartate, and glutamate metabolism 24 7 3.04E-08 17.31 1.64E-06 8.22E-07 6.09 0.75404 
Histidine metabolism 44 3 3.04E-08 17.307 1.64E-06 8.22E-07 6.09 0.14039 
Arginine and proline metabolism 77 8 5.05E-08 16.801 2.63E-06 9.09E-07 6.04 0.41398 
Nitrogen metabolism 39 10 1.64E-07 15.621 8.38E-06 2.22E-06 5.65 0.0083 
Pantothenate and CoA biosynthesis 27 3 6.14E-07 14.304 3.07E-05 5.49E-06 5.26 0.00854 
D-Glutamine and D-glutamate metabolism 11 2 6.49E-07 14.247 3.18E-05 5.49E-06 5.26 0.13904 
Aminoacyl-tRNA biosynthesis 75 18 7.11E-07 14.156 3.41E-05 5.49E-06 5.26 0.22536 
Phenylalanine metabolism 45 4 3.12E-06 12.677 0.00014675 2.11E-05 4.68 0.11906 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 3.97E-06 12.437 0.00018248 2.22E-05 4.65 0.008 
Valine, leucine and isoleucine degradation 40 3 4.11E-06 12.403 0.00018473 2.22E-05 4.65 0.0713 
Valine, leucine and isoleucine biosynthesis 27 4 5.81E-06 12.056 0.00025573 2.85E-05 4.54 0.0265 
Porphyrin and chlorophyll metabolism 104 3 2.17E-05 10.74 0.00093113 9.74E-05 4.01 0 
Glycine, serine and threonine metabolism 48 5 7.57E-05 9.4892 0.0031778 0.00031429 3.50 0.42039 
Pyrimidine metabolism 60 1 9.27E-05 9.2861 0.003801 0.00034339 3.46 0 
beta-Alanine metabolism 28 3 9.54E-05 9.2576 0.0038154 0.00034339 3.46 0.01119 
D-Arginine and D-ornithine metabolism 8 2 0.0001725 8.6653 0.0067262 0.00058207 3.24 0 
Propanoate metabolism 35 3 0.0001857 8.5912 0.0070579 0.00058998 3.23 0.05474 
Cyanoamino acid metabolism 16 4 0.0002083 8.4765 0.0077074 0.00062492 3.20 0 
Cysteine and methionine metabolism 56 4 0.0005912 7.4334 0.021283 0.0016802 2.77 0.05003 
Sphingolipid metabolism 25 1 0.0020402 6.1947 0.071409 0.0052463 2.28 0 
Sulfur metabolism 18 1 0.0020402 6.1947 0.071409 0.0052463 2.28 0 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.0021408 6.1466 0.071409 0.0052546 2.28 0 
Thiamine metabolism 24 2 0.0026805 5.9217 0.085777 0.0062934 2.20 0 
Biotin metabolism 11 1 0.0041962 5.4736 0.13008 0.0094415 2.02 0 
alpha-Linolenic acid metabolism 29 1 0.0071137 4.9457 0.21341 0.014865 1.83 0.20335 
Tyrosine metabolism 76 3 0.0071573 4.9396 0.21341 0.014865 1.83 0.04724 
Glutathione metabolism 38 5 0.0080413 4.8232 0.22516 0.016083 1.79 0.02214 
Lysine biosynthesis 32 4 0.0084714 4.7711 0.22873 0.016338 1.79 0.15084 
Purine metabolism 92 7 0.010977 4.5119 0.28541 0.020441 1.69 0.14975 
Primary bile acid biosynthesis 47 1 0.015356 4.1762 0.3839 0.027641 1.56 0.00822 
Fatty acid metabolism 50 3 0.027515 3.593 0.66035 0.047929 1.32 0.2426 
Lysine degradation 47 3 0.029995 3.5067 0.68989 0.050617 1.30 0.14675 
Methane metabolism 34 3 0.047709 3.0426 1 0.07807 1.11 0.05444 
Linoleic acid metabolism 15 1 0.053804 2.9224 1 0.085454 1.07 0.65625 
Butanoate metabolism 40 4 0.080677 2.5173 1 0.12447 0.90 0.10672 
Nicotinate and nicotinamide metabolism 44 4 0.10798 2.2258 1 0.16197 0.79 0.0015 
Selenoamino acid metabolism 22 1 0.11581 2.1558 1 0.16902 0.77 0 
Riboflavin metabolism 21 2 0.12698 2.0637 1 0.18044 0.74 0 
Folate biosynthesis 42 1 0.14637 1.9216 1 0.20267 0.69 0 
Tryptophan metabolism 79 2 0.17739 1.7294 1 0.23948 0.62 0.10853 
Starch and sucrose metabolism 50 1 0.35529 1.0348 1 0.43603 0.36 0.01703 
Galactose metabolism 41 1 0.35529 1.0348 1 0.43603 0.36 0.00276 
Pentose phosphate pathway 32 1 0.35529 1.0348 1 0.43603 0.36 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.35529 1.0348 1 0.43603 0.36 0 
Pyruvate metabolism 32 2 0.3971 0.92357 1 0.47652 0.32 0.24876 
Taurine and hypotaurine metabolism 20 2 0.52013 0.65368 1 0.61059 0.21 0.03237 
Citrate cycle (TCA cycle) 20 5 0.57655 0.5507 1 0.66242 0.18 0.17318 
Glycolysis or Gluconeogenesis 31 2 0.73106 0.31326 1 0.77708 0.11 0.04202 
Synthesis and degradation of ketone bodies 6 1 0.73391 0.30937 1 0.77708 0.11 0 
Inositol phosphate metabolism 39 1 0.73391 0.30937 1 0.77708 0.11 0 
Terpenoid backbone biosynthesis 33 1 0.73391 0.30937 1 0.77708 0.11 0 
Glyoxylate and dicarboxylate metabolism 50 4 0.76612 0.26642 1 0.79558 0.10 0.02984 
Fatty acid biosynthesis 49 6 0.83257 0.18324 1 0.84669 0.07 0.0218 
Fatty acid elongation in mitochondria 27 2 0.84669 0.16642 1 0.84669 0.07 0.26765 
 Table S3. Pathway Analysis of heart tissue comparing control with cardiac arrest. 
Pathways Total 
Compounds 
Hits Raw p neg log 
p-value
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
Tyrosine metabolism 76 3 0.00050009 7.6007 0.027005 0.014416 1.84 0.04724 
Phenylalanine metabolism 45 4 0.00077928 7.1571 0.041302 0.014416 1.84 0.11906 
Alanine, aspartate and glutamate metabolism 24 7 0.00080088 7.1298 0.041646 0.014416 1.84 0.75404 
Citrate cycle (TCA cycle) 20 5 0.0011822 6.7404 0.060292 0.01596 1.80 0.17318 
Butanoate metabolism 40 4 0.0016825 6.3875 0.084126 0.018171 1.74 0.10672 
Nicotinate and nicotinamide metabolism 44 4 0.0022504 6.0966 0.11027 0.020254 1.69 0.0015 
Glyoxylate and dicarboxylate metabolism 50 4 0.0031708 5.7538 0.1522 0.024387 1.61 0.02984 
Propanoate metabolism 35 3 0.0036129 5.6233 0.1698 0.024387 1.61 0.05474 
Folate biosynthesis 42 1 0.0076924 4.8675 0.35385 0.046154 1.34 0 
Arginine and proline metabolism 77 8 0.016139 4.1265 0.72626 0.087151 1.06 0.41398 
Riboflavin metabolism 21 2 0.031855 3.4466 1 0.15638 0.81 0 
Glycine, serine and threonine metabolism 48 5 0.042672 3.1542 1 0.16665 0.78 0.42039 
Lysine biosynthesis 32 4 0.044959 3.102 1 0.16665 0.78 0.15084 
Histidine metabolism 44 3 0.045349 3.0934 1 0.16665 0.78 0.14039 
Porphyrin and chlorophyll metabolism 104 3 0.047422 3.0487 1 0.16665 0.78 0 
Aminoacyl-tRNA biosynthesis 75 18 0.049734 3.0011 1 0.16665 0.78 0.22536 
Pantothenate and CoA biosynthesis 27 3 0.052463 2.9476 1 0.16665 0.78 0.00854 
Fatty acid biosynthesis 49 6 0.060572 2.8039 1 0.18171 0.74 0.0218 
Valine, leucine and isoleucine biosynthesis 27 4 0.070053 2.6585 1 0.1991 0.70 0.0265 
Purine metabolism 92 7 0.083485 2.4831 1 0.22541 0.65 0.14975 
Cysteine and methionine metabolism 56 4 0.092977 2.3754 1 0.23802 0.62 0.05003 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.1 2.3026 1 0.23802 0.62 0.008 
Pyruvate metabolism 32 2 0.10138 2.2889 1 0.23802 0.62 0.24876 
Glutathione metabolism 38 5 0.1102 2.2055 1 0.24795 0.61 0.02214 
beta-Alanine metabolism 28 3 0.14264 1.9475 1 0.28327 0.55 0.01119 
Selenoamino acid metabolism 22 1 0.14519 1.9297 1 0.28327 0.55 0 
Valine, leucine and isoleucine degradation 40 3 0.14551 1.9275 1 0.28327 0.55 0.0713 
D-Arginine and D-ornithine metabolism 8 2 0.14688 1.9181 1 0.28327 0.55 0 
Fatty acid elongation in mitochondria 27 2 0.15625 1.8563 1 0.29094 0.54 0.26765 
Fatty acid metabolism 50 3 0.16499 1.8019 1 0.29699 0.53 0.2426 
Tryptophan metabolism 79 2 0.21296 1.5466 1 0.37097 0.43 0.10853 
Taurine and hypotaurine metabolism 20 2 0.23192 1.4613 1 0.38209 0.42 0.03237 
Cyanoamino acid metabolism 16 4 0.24901 1.3902 1 0.38209 0.42 0 
Linoleic acid metabolism 15 1 0.25259 1.376 1 0.38209 0.42 0.65625 
Glycolysis or Gluconeogenesis 31 2 0.27066 1.3069 1 0.38209 0.42 0.04202 
Synthesis and degradation of ketone bodies 6 1 0.2709 1.306 1 0.38209 0.42 0 
Inositol phosphate metabolism 39 1 0.2709 1.306 1 0.38209 0.42 0 
Terpenoid backbone biosynthesis 33 1 0.2709 1.306 1 0.38209 0.42 0 
Nitrogen metabolism 39 10 0.28481 1.2559 1 0.38209 0.42 0.0083 
Starch and sucrose metabolism 50 1 0.30425 1.1899 1 0.38209 0.42 0.01703 
Galactose metabolism 41 1 0.30425 1.1899 1 0.38209 0.42 0.00276 
Pentose phosphate pathway 32 1 0.30425 1.1899 1 0.38209 0.42 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.30425 1.1899 1 0.38209 0.42 0 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.33483 1.0941 1 0.41093 0.39 0 
Lysine degradation 47 3 0.36126 1.0182 1 0.43351 0.36 0.14675 
Methane metabolism 34 3 0.40722 0.89839 1 0.47804 0.32 0.05444 
D-Glutamine and D-glutamate metabolism 11 2 0.45129 0.79565 1 0.5185 0.29 0.13904 
Primary bile acid biosynthesis 47 1 0.46768 0.75997 1 0.52614 0.28 0.00822 
Thiamine metabolism 24 2 0.5079 0.67746 1 0.54974 0.26 0 
Sphingolipid metabolism 25 1 0.5192 0.65547 1 0.54974 0.26 0 
Sulfur metabolism 18 1 0.5192 0.65547 1 0.54974 0.26 0 
Biotin metabolism 11 1 0.65132 0.42875 1 0.67637 0.17 0 
alpha-Linolenic acid metabolism 29 1 0.79122 0.23419 1 0.80614 0.09 0.20335 
Pyrimidine metabolism 60 1 0.84144 0.17264 1 0.84144 0.07 0 
 Table S4. Pathway Analysis of heart tissue comparing control with CPB-resuscitation. 
Pathways Total 
Compounds 
Hits Raw p neg log p-
value 
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
Aminoacyl-tRNA biosynthesis 75 18 0.0004338 7.7429 0.023425 0.023425 1.63 0.22536 
Citrate cycle (TCA cycle) 20 5 0.001377 6.5879 0.072981 0.028344 1.55 0.17318 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.0015747 6.4537 0.081882 0.028344 1.55 0.008 
Glycine, serine and threonine metabolism 48 5 0.0022435 6.0997 0.11442 0.030287 1.52 0.42039 
Phenylalanine metabolism 45 4 0.0028398 5.864 0.14199 0.03067 1.51 0.11906 
Tyrosine metabolism 76 3 0.0034882 5.6584 0.17092 0.031394 1.50 0.04724 
Glyoxylate and dicarboxylate metabolism 50 4 0.0044446 5.4161 0.21334 0.031475 1.50 0.02984 
Arginine and proline metabolism 77 8 0.0049982 5.2987 0.23492 0.031475 1.50 0.41398 
Alanine, aspartate and glutamate metabolism 24 7 0.0052458 5.2503 0.24131 0.031475 1.50 0.75404 
Nicotinate and nicotinamide metabolism 44 4 0.0062718 5.0717 0.28223 0.031614 1.50 0.0015 
Butanoate metabolism 40 4 0.0064399 5.0452 0.28335 0.031614 1.50 0.10672 
Propanoate metabolism 35 3 0.018371 3.997 0.78994 0.082668 1.08 0.05474 
Histidine metabolism 44 3 0.020399 3.8923 0.85674 0.084654 1.07 0.14039 
Porphyrin and chlorophyll metabolism 104 3 0.021947 3.8191 0.89984 0.084654 1.07 0 
Nitrogen metabolism 39 10 0.039178 3.2396 1 0.14104 0.85 0.0083 
Lysine biosynthesis 32 4 0.063211 2.7613 1 0.20437 0.69 0.15084 
Fatty acid biosynthesis 49 6 0.06548 2.726 1 0.20437 0.69 0.0218 
Tryptophan metabolism 79 2 0.068124 2.6864 1 0.20437 0.69 0.10853 
Pyruvate metabolism 32 2 0.075766 2.5801 1 0.21533 0.67 0.24876 
Valine, leucine and isoleucine biosynthesis 27 4 0.10004 2.3022 1 0.2701 0.57 0.0265 
beta-Alanine metabolism 28 3 0.13293 2.0179 1 0.34182 0.47 0.01119 
Purine metabolism 92 7 0.17949 1.7176 1 0.41767 0.38 0.14975 
D-Arginine and D-ornithine metabolism 8 2 0.18302 1.6982 1 0.41767 0.38 0 
Pantothenate and CoA biosynthesis 27 3 0.18563 1.684 1 0.41767 0.38 0.00854 
Valine, leucine and isoleucine degradation 40 3 0.2139 1.5422 1 0.43785 0.36 0.0713 
Fatty acid elongation in mitochondria 27 2 0.22185 1.5057 1 0.43785 0.36 0.26765 
Cyanoamino acid metabolism 16 4 0.22387 1.4967 1 0.43785 0.36 0 
Sphingolipid metabolism 25 1 0.23519 1.4474 1 0.43785 0.36 0 
Sulfur metabolism 18 1 0.23519 1.4474 1 0.43785 0.36 0 
Primary bile acid biosynthesis 47 1 0.24567 1.4038 1 0.43785 0.36 0.00822 
Cysteine and methionine metabolism 56 4 0.25136 1.3809 1 0.43785 0.36 0.05003 
Linoleic acid metabolism 15 1 0.26776 1.3177 1 0.45184 0.35 0.65625 
Fatty acid metabolism 50 3 0.30564 1.1853 1 0.48348 0.32 0.2426 
Thiamine metabolism 24 2 0.32367 1.128 1 0.48348 0.32 0 
Methane metabolism 34 3 0.33081 1.1062 1 0.48348 0.32 0.05444 
D-Glutamine and D-glutamate metabolism 11 2 0.33267 1.1006 1 0.48348 0.32 0.13904 
Synthesis and degradation of ketone bodies 6 1 0.34918 1.0522 1 0.48348 0.32 0 
Inositol phosphate metabolism 39 1 0.34918 1.0522 1 0.48348 0.32 0 
Terpenoid backbone biosynthesis 33 1 0.34918 1.0522 1 0.48348 0.32 0 
Selenoamino acid metabolism 22 1 0.36554 1.0064 1 0.49085 0.31 0 
Taurine and hypotaurine metabolism 20 2 0.37268 0.98703 1 0.49085 0.31 0.03237 
alpha-Linolenic acid metabolism 29 1 0.38472 0.95523 1 0.49464 0.31 0.20335 
Glutathione metabolism 38 5 0.40752 0.89766 1 0.51177 0.29 0.02214 
Glycolysis or Gluconeogenesis 31 2 0.43042 0.84299 1 0.52825 0.28 0.04202 
Lysine degradation 47 3 0.44394 0.81208 1 0.53272 0.27 0.14675 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.5504 0.59712 1 0.64612 0.19 0 
Pyrimidine metabolism 60 1 0.67742 0.38947 1 0.77831 0.11 0 
Riboflavin metabolism 21 2 0.77618 0.25337 1 0.8732 0.06 0 
Folate biosynthesis 42 1 0.8495 0.16311 1 0.93618 0.03 0 
Starch and sucrose metabolism 50 1 0.98214 0.018023 1 0.99254 0.00 0.01703 
Galactose metabolism 41 1 0.98214 0.018023 1 0.99254 0.00 0.00276 
Pentose phosphate pathway 32 1 0.98214 0.018023 1 0.99254 0.00 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.98214 0.018023 1 0.99254 0.00 0 
Biotin metabolism 11 1 0.99254 0.0074851 1 0.99254 0.00 0 
 Table S5. Pathway Analysis of kidney tissue comparing control with cardiac arrest. 
Pathways Total 
Compounds 
Hits Raw p neg log p-
value 
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
Lysine biosynthesis 32 4 0.00029101 8.1422 0.015714 0.01002 2.00 0.15084 
Purine metabolism 92 7 0.00037111 7.899 0.019669 0.01002 2.00 0.14975 
Nitrogen metabolism 39 10 0.0019227 6.254 0.099982 0.019234 1.72 0.0083 
Phenylalanine metabolism 45 4 0.0019415 6.2443 0.099982 0.019234 1.72 0.11906 
Arginine and proline metabolism 77 8 0.0029826 5.815 0.14913 0.019234 1.72 0.41398 
D-Arginine and D-ornithine metabolism 8 2 0.003111 5.7728 0.15244 0.019234 1.72 0 
Nicotinate and nicotinamide metabolism 44 4 0.0031628 5.7563 0.15244 0.019234 1.72 0.0015 
Pyrimidine metabolism 60 1 0.0033124 5.7101 0.15568 0.019234 1.72 0 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.0042203 5.4678 0.19414 0.019234 1.72 0.008 
Cysteine and methionine metabolism 56 4 0.0046097 5.3796 0.20744 0.019234 1.72 0.05003 
Aminoacyl-tRNA biosynthesis 75 18 0.0049735 5.3036 0.21883 0.019234 1.72 0.22536 
Glycine, serine and threonine metabolism 48 5 0.0051371 5.2713 0.22089 0.019234 1.72 0.42039 
Sphingolipid metabolism 25 1 0.0051425 5.2702 0.22089 0.019234 1.72 0 
Sulfur metabolism 18 1 0.0051425 5.2702 0.22089 0.019234 1.72 0 
Cyanoamino acid metabolism 16 4 0.0053427 5.232 0.22089 0.019234 1.72 0 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.0062803 5.0703 0.24493 0.021196 1.67 0 
Thiamine metabolism 24 2 0.0080993 4.816 0.30777 0.025727 1.59 0 
Biotin metabolism 11 1 0.010296 4.576 0.38094 0.030358 1.52 0 
D-Glutamine and D-glutamate metabolism 11 2 0.010825 4.5259 0.3897 0.030358 1.52 0.13904 
Alanine, aspartate and glutamate metabolism 24 7 0.011244 4.488 0.39352 0.030358 1.52 0.75404 
beta-Alanine metabolism 28 3 0.01639 4.1111 0.55728 0.042147 1.38 0.01119 
Methane metabolism 34 3 0.018866 3.9704 0.62257 0.046307 1.33 0.05444 
Lysine degradation 47 3 0.021418 3.8435 0.68537 0.049361 1.31 0.14675 
Glutathione metabolism 38 5 0.021938 3.8195 0.68537 0.049361 1.31 0.02214 
Primary bile acid biosynthesis 47 1 0.023866 3.7353 0.71597 0.05155 1.29 0.00822 
Histidine metabolism 44 3 0.028995 3.5406 0.84086 0.060221 1.22 0.14039 
Tryptophan metabolism 79 2 0.030189 3.5003 0.8453 0.060378 1.22 0.10853 
Fatty acid metabolism 50 3 0.05956 2.8208 1 0.11219 0.95 0.2426 
Tyrosine metabolism 76 3 0.06025 2.8093 1 0.11219 0.95 0.04724 
Fatty acid elongation in mitochondria 27 2 0.063273 2.7603 1 0.11389 0.94 0.26765 
Selenoamino acid metabolism 22 1 0.10571 2.2471 1 0.18413 0.73 0 
Fatty acid biosynthesis 49 6 0.1154 2.1594 1 0.18756 0.73 0.0218 
Porphyrin and chlorophyll metabolism 104 3 0.11554 2.1582 1 0.18756 0.73 0 
Taurine and hypotaurine metabolism 20 2 0.11809 2.1363 1 0.18756 0.73 0.03237 
Pyruvate metabolism 32 2 0.13353 2.0134 1 0.20602 0.69 0.24876 
Pantothenate and CoA biosynthesis 27 3 0.17149 1.7632 1 0.24678 0.61 0.00854 
Synthesis and degradation of ketone bodies 6 1 0.17823 1.7247 1 0.24678 0.61 0 
Inositol phosphate metabolism 39 1 0.17823 1.7247 1 0.24678 0.61 0 
Terpenoid backbone biosynthesis 33 1 0.17823 1.7247 1 0.24678 0.61 0 
Valine, leucine and isoleucine biosynthesis 27 4 0.19042 1.6585 1 0.25256 0.60 0.0265 
Valine, leucine and isoleucine degradation 40 3 0.19176 1.6515 1 0.25256 0.60 0.0713 
Riboflavin metabolism 21 2 0.22997 1.4698 1 0.29567 0.53 0 
Glycolysis or Gluconeogenesis 31 2 0.24447 1.4087 1 0.30701 0.51 0.04202 
Citrate cycle (TCA cycle) 20 5 0.25874 1.3519 1 0.31755 0.50 0.17318 
Glyoxylate and dicarboxylate metabolism 50 4 0.27644 1.2858 1 0.33173 0.48 0.02984 
Butanoate metabolism 40 4 0.28503 1.2551 1 0.33461 0.48 0.10672 
alpha-Linolenic acid metabolism 29 1 0.42994 0.84411 1 0.49398 0.31 0.20335 
Folate biosynthesis 42 1 0.55557 0.58777 1 0.62501 0.20 0 
Propanoate metabolism 35 3 0.63049 0.46126 1 0.69482 0.16 0.05474 
Linoleic acid metabolism 15 1 0.6887 0.37295 1 0.74379 0.13 0.65625 
Starch and sucrose metabolism 50 1 0.7912 0.2342 1 0.7912 0.10 0.01703 
Galactose metabolism 41 1 0.7912 0.2342 1 0.7912 0.10 0.00276 
Pentose phosphate pathway 32 1 0.7912 0.2342 1 0.7912 0.10 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.7912 0.2342 1 0.7912 0.10 0 
 Table S6. Pathway Analysis of kidney tissue comparing control with CPB-resuscitation. 
Pathways Total 
Compounds 
Hits Raw p neg log p-
value 
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
Nicotinate and nicotinamide metabolism 44 4 1.24E-06 13.601 6.69E-05 2.29E-05 4.64 0.0015 
Phenylalanine metabolism 45 4 1.31E-06 13.549 6.92E-05 2.29E-05 4.64 0.11906 
Citrate cycle (TCA cycle) 20 5 1.37E-06 13.498 7.14E-05 2.29E-05 4.64 0.17318 
Glyoxylate and dicarboxylate metabolism 50 4 1.70E-06 13.288 8.65E-05 2.29E-05 4.64 0.02984 
Tyrosine metabolism 76 3 5.19E-06 12.169 0.00025937 4.57E-05 4.34 0.04724 
Alanine, aspartate and glutamate metabolism 24 7 6.08E-06 12.011 0.00029773 4.57E-05 4.34 0.75404 
Cysteine and methionine metabolism 56 4 6.16E-06 11.998 0.00029773 4.57E-05 4.34 0.05003 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 6.77E-06 11.903 0.00031811 4.57E-05 4.34 0 
Arginine and proline metabolism 77 8 7.82E-06 11.759 0.00035981 4.69E-05 4.33 0.41398 
Glycine, serine and threonine metabolism 48 5 1.26E-05 11.285 0.00056494 6.78E-05 4.17 0.42039 
Thiamine metabolism 24 2 2.26E-05 10.698 0.00099433 0.00011094 3.95 0 
D-Arginine and D-ornithine metabolism 8 2 3.05E-05 10.399 0.00131 0.00013709 3.86 0 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 3.81E-05 10.176 0.0015984 0.00015809 3.80 0.008 
Tryptophan metabolism 79 2 7.21E-05 9.538 0.0029546 0.0002635 3.58 0.10853 
Aminoacyl-tRNA biosynthesis 75 18 7.32E-05 9.5224 0.0029546 0.0002635 3.58 0.22536 
Cyanoamino acid metabolism 16 4 7.89E-05 9.4474 0.0030769 0.00026627 3.57 0 
Nitrogen metabolism 39 10 9.54E-05 9.2572 0.003626 0.0003031 3.52 0.0083 
Lysine biosynthesis 32 4 0.00013946 8.8777 0.00516 0.00041837 3.38 0.15084 
Butanoate metabolism 40 4 0.00019354 8.55 0.0069676 0.00055007 3.26 0.10672 
Glutathione metabolism 38 5 0.00029348 8.1337 0.010272 0.00077617 3.11 0.02214 
Pyruvate metabolism 32 2 0.00031232 8.0715 0.010619 0.00077617 3.11 0.24876 
Primary bile acid biosynthesis 47 1 0.00031622 8.0591 0.010619 0.00077617 3.11 0.00822 
Histidine metabolism 44 3 0.00041597 7.7849 0.013311 0.00097662 3.01 0.14039 
Sphingolipid metabolism 25 1 0.001126 6.7891 0.034905 0.0024321 2.61 0 
Sulfur metabolism 18 1 0.001126 6.7891 0.034905 0.0024321 2.61 0 
Porphyrin and chlorophyll metabolism 104 3 0.0013803 6.5855 0.040028 0.0028158 2.55 0 
beta-Alanine metabolism 28 3 0.0014079 6.5656 0.040028 0.0028158 2.55 0.01119 
Methane metabolism 34 3 0.001669 6.3956 0.045062 0.0031553 2.50 0.05444 
Fatty acid metabolism 50 3 0.0016945 6.3804 0.045062 0.0031553 2.50 0.2426 
alpha-Linolenic acid metabolism 29 1 0.0021024 6.1647 0.052559 0.0037843 2.42 0.20335 
Pantothenate and CoA biosynthesis 27 3 0.0024915 5.9949 0.059796 0.0043401 2.36 0.00854 
Valine, leucine and isoleucine biosynthesis 27 4 0.0032559 5.7273 0.074887 0.0054944 2.26 0.0265 
Lysine degradation 47 3 0.0056789 5.171 0.12494 0.0092927 2.03 0.14675 
Fatty acid elongation in mitochondria 27 2 0.0063416 5.0606 0.13317 0.010072 2.00 0.26765 
Pyrimidine metabolism 60 1 0.0070059 4.961 0.14012 0.010809 1.97 0 
Purine metabolism 92 7 0.0078614 4.8458 0.14937 0.011792 1.93 0.14975 
Propanoate metabolism 35 3 0.0083512 4.7853 0.15032 0.012188 1.91 0.05474 
D-Glutamine and D-glutamate metabolism 11 2 0.010338 4.5719 0.17574 0.014691 1.83 0.13904 
Fatty acid biosynthesis 49 6 0.019007 3.9629 0.30412 0.026318 1.58 0.0218 
Folate biosynthesis 42 1 0.022427 3.7975 0.3364 0.030276 1.52 0 
Biotin metabolism 11 1 0.023189 3.7641 0.3364 0.030542 1.52 0 
Valine, leucine and isoleucine degradation 40 3 0.02687 3.6168 0.34931 0.034547 1.46 0.0713 
Linoleic acid metabolism 15 1 0.028899 3.5439 0.34931 0.036292 1.44 0.65625 
Synthesis and degradation of ketone bodies 6 1 0.041945 3.1714 0.46139 0.049239 1.31 0 
Inositol phosphate metabolism 39 1 0.041945 3.1714 0.46139 0.049239 1.31 0 
Terpenoid backbone biosynthesis 33 1 0.041945 3.1714 0.46139 0.049239 1.31 0 
Riboflavin metabolism 21 2 0.050903 2.9778 0.46139 0.058484 1.23 0 
Taurine and hypotaurine metabolism 20 2 0.053481 2.9284 0.46139 0.060166 1.22 0.03237 
Glycolysis or Gluconeogenesis 31 2 0.061534 2.7882 0.46139 0.067813 1.17 0.04202 
Selenoamino acid metabolism 22 1 0.52693 0.64069 1 0.56908 0.24 0 
Starch and sucrose metabolism 50 1 0.59928 0.51203 1 0.59928 0.22 0.01703 
Galactose metabolism 41 1 0.59928 0.51203 1 0.59928 0.22 0.00276 
Pentose phosphate pathway 32 1 0.59928 0.51203 1 0.59928 0.22 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.59928 0.51203 1 0.59928 0.22 0 
 Table S7. Pathway Analysis of liver tissue comparing control with cardiac arrest. 
Pathways Total 
Compounds 
Hits Raw p neg log p-
value 
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
alpha-Linolenic acid metabolism 29 1 0.0014237 6.5545 0.076881 0.076881 1.11 0.20335 
Linoleic acid metabolism 15 1 0.0033765 5.6909 0.17895 0.086157 1.06 0.65625 
Fatty acid metabolism 50 3 0.0047865 5.342 0.2489 0.086157 1.06 0.2426 
Fatty acid biosynthesis 49 6 0.010908 4.5183 0.55629 0.1337 0.87 0.0218 
Purine metabolism 92 7 0.01238 4.3917 0.61898 0.1337 0.87 0.14975 
Fatty acid elongation in mitochondria 27 2 0.019508 3.937 0.95587 0.17557 0.76 0.26765 
Riboflavin metabolism 21 2 0.023461 3.7524 1 0.18098 0.74 0 
Nicotinate and nicotinamide metabolism 44 4 0.035419 3.3405 1 0.20347 0.69 0.0015 
Pantothenate and CoA biosynthesis 27 3 0.039067 3.2425 1 0.20347 0.69 0.00854 
Glutathione metabolism 38 5 0.046815 3.0616 1 0.20347 0.69 0.02214 
Tryptophan metabolism 79 2 0.05069 2.982 1 0.20347 0.69 0.10853 
Synthesis and degradation of ketone bodies 6 1 0.052752 2.9421 1 0.20347 0.69 0 
Inositol phosphate metabolism 39 1 0.052752 2.9421 1 0.20347 0.69 0 
Terpenoid backbone biosynthesis 33 1 0.052752 2.9421 1 0.20347 0.69 0 
Glycolysis or Gluconeogenesis 31 2 0.064108 2.7472 1 0.23079 0.64 0.04202 
Folate biosynthesis 42 1 0.071947 2.6318 1 0.24282 0.61 0 
D-Arginine and D-ornithine metabolism 8 2 0.0914 2.3925 1 0.28787 0.54 0 
Valine, leucine and isoleucine degradation 40 3 0.095956 2.3439 1 0.28787 0.54 0.0713 
Pyruvate metabolism 32 2 0.11632 2.1514 1 0.3306 0.48 0.24876 
Propanoate metabolism 35 3 0.14731 1.9152 1 0.38008 0.42 0.05474 
Valine, leucine and isoleucine biosynthesis 27 4 0.15165 1.8862 1 0.38008 0.42 0.0265 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.15485 1.8653 1 0.38008 0.42 0 
Taurine and hypotaurine metabolism 20 2 0.16667 1.7917 1 0.39132 0.41 0.03237 
Pyrimidine metabolism 60 1 0.20545 1.5825 1 0.43868 0.36 0 
beta-Alanine metabolism 28 3 0.20738 1.5732 1 0.43868 0.36 0.01119 
Lysine degradation 47 3 0.21122 1.5549 1 0.43868 0.36 0.14675 
Arginine and proline metabolism 77 8 0.24481 1.4073 1 0.48962 0.31 0.41398 
Methane metabolism 34 3 0.27121 1.3049 1 0.51615 0.29 0.05444 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.279 1.2765 1 0.51615 0.29 0.008 
Glyoxylate and dicarboxylate metabolism 50 4 0.29044 1.2364 1 0.51615 0.29 0.02984 
Nitrogen metabolism 39 10 0.30007 1.2037 1 0.51615 0.29 0.0083 
Butanoate metabolism 40 4 0.31418 1.1578 1 0.51615 0.29 0.10672 
Lysine biosynthesis 32 4 0.31542 1.1538 1 0.51615 0.29 0.15084 
Aminoacyl-tRNA biosynthesis 75 18 0.33769 1.0856 1 0.51927 0.28 0.22536 
Thiamine metabolism 24 2 0.34435 1.0661 1 0.51927 0.28 0 
Citrate cycle (TCA cycle) 20 5 0.34726 1.0577 1 0.51927 0.28 0.17318 
Biotin metabolism 11 1 0.3558 1.0334 1 0.51927 0.28 0 
D-Glutamine and D-glutamate metabolism 11 2 0.36666 1.0033 1 0.52104 0.28 0.13904 
Tyrosine metabolism 76 3 0.41191 0.88696 1 0.56457 0.25 0.04724 
Cyanoamino acid metabolism 16 4 0.43582 0.83053 1 0.56457 0.25 0 
Alanine, aspartate and glutamate metabolism 24 7 0.44031 0.82028 1 0.56457 0.25 0.75404 
Phenylalanine metabolism 45 4 0.44315 0.81385 1 0.56457 0.25 0.11906 
Selenoamino acid metabolism 22 1 0.49087 0.71159 1 0.56457 0.25 0 
Starch and sucrose metabolism 50 1 0.49139 0.71052 1 0.56457 0.25 0.01703 
Galactose metabolism 41 1 0.49139 0.71052 1 0.56457 0.25 0.00276 
Pentose phosphate pathway 32 1 0.49139 0.71052 1 0.56457 0.25 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.49139 0.71052 1 0.56457 0.25 0 
Primary bile acid biosynthesis 47 1 0.51602 0.6616 1 0.58053 0.24 0.00822 
Glycine, serine and threonine metabolism 48 5 0.54352 0.60969 1 0.59898 0.22 0.42039 
Sphingolipid metabolism 25 1 0.58147 0.54219 1 0.61568 0.21 0 
Sulfur metabolism 18 1 0.58147 0.54219 1 0.61568 0.21 0 
Porphyrin and chlorophyll metabolism 104 3 0.59755 0.51492 1 0.62032 0.21 0 
Cysteine and methionine metabolism 56 4 0.60883 0.49621 1 0.62032 0.21 0.05003 
Histidine metabolism 44 3 0.62887 0.46384 1 0.62887 0.20 0.14039 
 Table S8. Pathway Analysis of liver tissue comparing control with CPB-resuscitation. 
Pathways Total 
Compounds 
Hits Raw p neg log p-
value 
Holm 
adjust. 
FDR neg log 
FDR 
Impact 
Fatty acid metabolism 50 3 0.01064 4.5431 0.57458 0.16246 0.79 0.2426 
Synthesis and degradation of ketone bodies 6 1 0.014841 4.2104 0.78657 0.16246 0.79 0 
Inositol phosphate metabolism 39 1 0.014841 4.2104 0.78657 0.16246 0.79 0 
Terpenoid backbone biosynthesis 33 1 0.014841 4.2104 0.78657 0.16246 0.79 0 
Glycolysis or Gluconeogenesis 31 2 0.015043 4.1968 0.78657 0.16246 0.79 0.04202 
Fatty acid elongation in mitochondria 27 2 0.024819 3.6962 1 0.22337 0.65 0.26765 
Tryptophan metabolism 79 2 0.029732 3.5155 1 0.22936 0.64 0.10853 
Pyruvate metabolism 32 2 0.045312 3.0942 1 0.30586 0.51 0.24876 
Glutathione metabolism 38 5 0.064768 2.737 1 0.36958 0.43 0.02214 
Purine metabolism 92 7 0.068441 2.6818 1 0.36958 0.43 0.14975 
Nicotinate and nicotinamide metabolism 44 4 0.085561 2.4585 1 0.39219 0.41 0.0015 
Lysine biosynthesis 32 4 0.087153 2.4401 1 0.39219 0.41 0.15084 
D-Arginine and D-ornithine metabolism 8 2 0.10233 2.2795 1 0.40591 0.39 0 
Glyoxylate and dicarboxylate metabolism 50 4 0.10563 2.2478 1 0.40591 0.39 0.02984 
Taurine and hypotaurine metabolism 20 2 0.11275 2.1825 1 0.40591 0.39 0.03237 
Propanoate metabolism 35 3 0.12048 2.1163 1 0.40662 0.39 0.05474 
Fatty acid biosynthesis 49 6 0.12968 2.0427 1 0.40754 0.39 0.0218 
Butanoate metabolism 40 4 0.15285 1.8783 1 0.40754 0.39 0.10672 
Citrate cycle (TCA cycle) 20 5 0.16016 1.8316 1 0.40754 0.39 0.17318 
Pantothenate and CoA biosynthesis 27 3 0.16054 1.8292 1 0.40754 0.39 0.00854 
Riboflavin metabolism 21 2 0.16108 1.8258 1 0.40754 0.39 0 
beta-Alanine metabolism 28 3 0.16604 1.7956 1 0.40754 0.39 0.01119 
Valine, leucine and isoleucine degradation 40 3 0.20352 1.592 1 0.47784 0.32 0.0713 
Folate biosynthesis 42 1 0.23501 1.4481 1 0.52878 0.28 0 
Lysine degradation 47 3 0.25994 1.3473 1 0.56147 0.25 0.14675 
Methane metabolism 34 3 0.29328 1.2266 1 0.56257 0.25 0.05444 
Valine, leucine and isoleucine biosynthesis 27 4 0.29833 1.2095 1 0.56257 0.25 0.0265 
Tyrosine metabolism 76 3 0.31333 1.1605 1 0.56257 0.25 0.04724 
Starch and sucrose metabolism 50 1 0.34847 1.0542 1 0.56257 0.25 0.01703 
Galactose metabolism 41 1 0.34847 1.0542 1 0.56257 0.25 0.00276 
Pentose phosphate pathway 32 1 0.34847 1.0542 1 0.56257 0.25 0 
Amino sugar and nucleotide sugar metabolism 88 1 0.34847 1.0542 1 0.56257 0.25 0 
Arginine and proline metabolism 77 8 0.3494 1.0515 1 0.56257 0.25 0.41398 
Phenylalanine metabolism 45 4 0.36201 1.0161 1 0.56257 0.25 0.11906 
Pyrimidine metabolism 60 1 0.36703 1.0023 1 0.56257 0.25 0 
Alanine, aspartate and glutamate metabolism 24 7 0.37505 0.98071 1 0.56257 0.25 0.75404 
Selenoamino acid metabolism 22 1 0.40696 0.89904 1 0.59394 0.23 0 
Nitrogen metabolism 39 10 0.45861 0.77955 1 0.64116 0.19 0.0083 
D-Glutamine and D-glutamate metabolism 11 2 0.46306 0.76989 1 0.64116 0.19 0.13904 
Histidine metabolism 44 3 0.51073 0.67191 1 0.66771 0.18 0.14039 
alpha-Linolenic acid metabolism 29 1 0.51908 0.6557 1 0.66771 0.18 0.20335 
Aminoacyl-tRNA biosynthesis 75 18 0.51933 0.65521 1 0.66771 0.18 0.22536 
Cysteine and methionine metabolism 56 4 0.56733 0.56681 1 0.70514 0.15 0.05003 
Primary bile acid biosynthesis 47 1 0.58115 0.54275 1 0.70514 0.15 0.00822 
Cyanoamino acid metabolism 16 4 0.58762 0.53167 1 0.70514 0.15 0 
Thiamine metabolism 24 2 0.64893 0.43243 1 0.75685 0.12 0 
Porphyrin and chlorophyll metabolism 104 3 0.6657 0.40692 1 0.75685 0.12 0 
Glycine, serine and threonine metabolism 48 5 0.67276 0.39637 1 0.75685 0.12 0.42039 
Linoleic acid metabolism 15 1 0.72639 0.31967 1 0.80051 0.10 0.65625 
Phenylalanine, tyrosine and tryptophan biosynthesis 27 3 0.76367 0.26962 1 0.82214 0.09 0.008 
Biotin metabolism 11 1 0.77646 0.25301 1 0.82214 0.09 0 
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.85527 0.15634 1 0.87066 0.06 0 
Sphingolipid metabolism 25 1 0.87066 0.1385 1 0.87066 0.06 0 
Sulfur metabolism 18 1 0.87066 0.1385 1 0.87066 0.06 0 
